Aukje K Mantel-Teeuwisse

Summary

Affiliation: Utrecht University
Country: The Netherlands

Publications

  1. doi request reprint Psychiatric and cardiovascular comorbidities in patients with diabetes mellitus starting antiobesity drugs
    Marjolein J Willemen
    Department of Pharmaceutical Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands
    Obesity (Silver Spring) 16:2331-5. 2008
  2. ncbi request reprint Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels
    A K Mantel-Teeuwisse
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, The Netherlands
    Drug Saf 24:443-56. 2001
  3. pmc Suboptimal choices and dosing of statins at start of therapy
    Aukje K Mantel-Teeuwisse
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Br J Clin Pharmacol 60:83-9. 2005
  4. pmc Recent trends in (under)treatment of hypercholesterolaemia in the Netherlands
    Aukje K Mantel-Teeuwisse
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Br J Clin Pharmacol 58:310-6. 2004
  5. ncbi request reprint Failure to continue lipid-lowering drug use following the withdrawal of cerivastatin
    Aukje K Mantel-Teeuwisse
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    Drug Saf 27:63-70. 2004
  6. pmc Undertreatment of hypercholesterolaemia: a population-based study
    A K Mantel-Teeuwisse
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, PO Box 80082, 3508 TB Utrecht, The Netherlands
    Br J Clin Pharmacol 55:389-97. 2003
  7. ncbi request reprint Myopathy due to statin/fibrate use in the Netherlands
    Aukje K Mantel-Teeuwisse
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands
    Ann Pharmacother 36:1957-60. 2002
  8. pmc Time trends in lipid lowering drug use in The Netherlands. Has the backlog of candidates for treatment been eliminated?
    Aukje K Mantel-Teeuwisse
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    Br J Clin Pharmacol 53:379-85. 2002
  9. ncbi request reprint Comparison of different methods to estimate prevalence of drug use by using pharmacy records
    A K Mantel-Teeuwisse
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, P O BOX 80082, 3508 TB, Utrecht, The Netherlands
    J Clin Epidemiol 54:1181-6. 2001
  10. ncbi request reprint Drug costs associated with non-adherence to cholesterol management guidelines for primary prevention of cardiovascular disease in an elderly population: the Rotterdam study
    Pearl D Gumbs
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceuticals Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Drugs Aging 23:733-41. 2006

Collaborators

Detail Information

Publications42

  1. doi request reprint Psychiatric and cardiovascular comorbidities in patients with diabetes mellitus starting antiobesity drugs
    Marjolein J Willemen
    Department of Pharmaceutical Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands
    Obesity (Silver Spring) 16:2331-5. 2008
    ..The baseline risk for psychiatric disorders and cardiovascular disease was found to be higher in patients with diabetes mellitus starting to use antiobesity drugs compared to patients with diabetes mellitus not starting such treatment...
  2. ncbi request reprint Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels
    A K Mantel-Teeuwisse
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, The Netherlands
    Drug Saf 24:443-56. 2001
    ..In cases of extreme hyperlipidaemia, medication use should be reassessed...
  3. pmc Suboptimal choices and dosing of statins at start of therapy
    Aukje K Mantel-Teeuwisse
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Br J Clin Pharmacol 60:83-9. 2005
    ..To assess dosing and determinants of the choice of statins among starters of statins...
  4. pmc Recent trends in (under)treatment of hypercholesterolaemia in the Netherlands
    Aukje K Mantel-Teeuwisse
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Br J Clin Pharmacol 58:310-6. 2004
    ..To assess recent trends in undertreatment of hypercholesterolaemia (1998-2002)...
  5. ncbi request reprint Failure to continue lipid-lowering drug use following the withdrawal of cerivastatin
    Aukje K Mantel-Teeuwisse
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    Drug Saf 27:63-70. 2004
    ..Persistence with lipid-lowering drug use is important in order for patients to gain full treatment benefit. The withdrawal of cerivastatin from the market may have affected persistence due to the fear of serious adverse effects...
  6. pmc Undertreatment of hypercholesterolaemia: a population-based study
    A K Mantel-Teeuwisse
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, PO Box 80082, 3508 TB Utrecht, The Netherlands
    Br J Clin Pharmacol 55:389-97. 2003
    ....
  7. ncbi request reprint Myopathy due to statin/fibrate use in the Netherlands
    Aukje K Mantel-Teeuwisse
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands
    Ann Pharmacother 36:1957-60. 2002
    ..To estimate the number of expected cases of myopathy based on the prevalence of lipid-lowering drug use, and to compare this number with the observed number of cases of myopathy due to lipid-lowering drug use in the Netherlands...
  8. pmc Time trends in lipid lowering drug use in The Netherlands. Has the backlog of candidates for treatment been eliminated?
    Aukje K Mantel-Teeuwisse
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    Br J Clin Pharmacol 53:379-85. 2002
    ..To assess time trends in lipid lowering drug use in The Netherlands...
  9. ncbi request reprint Comparison of different methods to estimate prevalence of drug use by using pharmacy records
    A K Mantel-Teeuwisse
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, P O BOX 80082, 3508 TB, Utrecht, The Netherlands
    J Clin Epidemiol 54:1181-6. 2001
    ..However, defined daily doses should not be used to estimate (point) prevalences of drug use because this measure is significantly influenced by prescribed dosage regimens...
  10. ncbi request reprint Drug costs associated with non-adherence to cholesterol management guidelines for primary prevention of cardiovascular disease in an elderly population: the Rotterdam study
    Pearl D Gumbs
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceuticals Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Drugs Aging 23:733-41. 2006
    ..However, several studies have established both undertreatment and non-guidelines-indicated treatment with statins, suggesting a suboptimal use of resources...
  11. pmc Regulatory scientific advice on non-inferiority drug trials
    Grace Wangge
    Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands Medicines Evaluation Board, Utrecht, The Netherlands
    PLoS ONE 8:e74818. 2013
    ..It is unlikely that regulatory guidelines can cover all therapeutic areas; therefore, in some cases regulatory scientific advice may be used as an opportunity for tailored advice. ..
  12. doi request reprint Determinants for successful marketing authorisation of orphan medicinal products in the EU
    Michelle Putzeist
    Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, The Netherlands
    Drug Discov Today 17:352-8. 2012
    ..In addition, high medical need seems to counterweigh uncertainties about the scientific evidence in the benefit-risk assessment of OMPs...
  13. doi request reprint Reasons for and time to discontinuation of rimonabant therapy: a modified prescription-event monitoring study
    Marjolein J C Willemen
    Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands
    Drug Saf 35:1147-58. 2012
    ..This non-persistence of therapy has been associated with an increased risk of adverse health outcomes...
  14. doi request reprint A cohort study exploring determinants of safety-related regulatory actions for biopharmaceuticals
    Hans C Ebbers
    Utrecht Institute for Pharmaceutical Sciences UIPS, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands
    Drug Saf 35:417-27. 2012
    ..The characteristics of biopharmaceuticals may require a tailored approach to their safety management. However, information on what tools and methods are employed to assess the safety of biopharmaceuticals post-authorization is lacking...
  15. pmc Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution
    Pearl D Gumbs
    Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Br J Clin Pharmacol 64:680-5. 2007
    ..To assess the potential annual savings due to generic and therapeutic substitution of statin therapy for the general Dutch population, taking the patients medical history into account...
  16. doi request reprint Safety-related regulatory actions for orphan drugs in the US and EU: a cohort study
    Harald E Heemstra
    Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, 3508 TB Utrecht, The Netherlands
    Drug Saf 33:127-37. 2010
    ..Several studies have been conducted on safety-related regulatory actions for drugs, but none of these have specifically focused on orphan drugs...
  17. ncbi request reprint Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes
    Anke Hilse Maitland-van der Zee
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Pharmacogenetics 13:219-23. 2003
    ..18 (CI 1.01-10.03) in men. The apoE genotype is associated with discontinuation of statins. This suggests that subjects who are genetically prone to develop hypercholesterolemia show the highest risk of discontinuation of treatment...
  18. pmc Prescribing behaviour according to Dutch and European guidelines on the management of hypercholesterolaemia (1992-1999)
    Aukje K Mantel-Teeuwisse
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Br J Clin Pharmacol 61:592-600. 2006
    ..The success of the full implementation of a new guideline may depend on the observed discrepancy between daily medical practice developed before the release of the guideline and new treatment recommendations issued by the guideline...
  19. doi request reprint Differences between post-authorization adverse drug reactions of biopharmaceuticals and small molecules
    Hans C Ebbers
    Division of Pharmacoepidemiology and Clinical Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, P O Box 80 082, 3508 TB Utrecht, The Netherlands
    BioDrugs 27:167-74. 2013
    ..However, it remains unclear how much of the observed differences can be attributed to differences in authorized indications of the two product groups...
  20. pmc The role of Periodic Safety Update Reports in the safety management of biopharmaceuticals
    Hans C Ebbers
    Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences UIPS, Faculty of Science, Utrecht University, P O Box 80 082, 3508 TB, Utrecht, The Netherlands
    Eur J Clin Pharmacol 69:217-26. 2013
    ..To describe and assess the outcomes of Periodic Safety Update Report (PSUR) evaluations of biopharmaceuticals...
  21. doi request reprint Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase
    Thijs J Giezen
    Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands
    Drug Saf 33:865-78. 2010
    ..However, in general there is limited data on the nature of spontaneously reported suspected ADRs for biologicals...
  22. doi request reprint Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumab
    Hans C Ebbers
    Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    Drug Discov Today 18:872-9. 2013
    ..On the basis of data available for the innovator product (bevacizumab) we will discuss strengths and weaknesses of preclinical and clinical models and explore the application of novel endpoints to the biosimilar comparability exercise. ..
  23. pmc Reimbursement restriction and moderate decrease in benzodiazepine use in general practice
    Joëlle M Hoebert
    Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands
    Ann Fam Med 10:42-9. 2012
    ..This study aims to assess the impact of this reimbursement restriction on benzodiazepine use in patients with newly diagnosed anxiety or sleeping disorder in general practice...
  24. doi request reprint Safety-related regulatory actions for biologicals approved in the United States and the European Union
    Thijs J Giezen
    Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht University, Utrecht, The Netherlands
    JAMA 300:1887-96. 2008
    ..Biologicals are a relatively new class of medicines that carry specific risks (eg, immunogenicity). However, limited information is available on the nature and timing of safety problems with their use that were identified after approval...
  25. doi request reprint Rituximab-induced thrombocytopenia: a cohort study
    Thijs J Giezen
    Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    Eur J Haematol 89:256-66. 2012
    ..More frequent monitoring of the platelet count is especially advised in patients treated in the oncology indication and/or with a low platelet count and high PDW...
  26. doi request reprint Do rheumatoid arthritis patients have equal access to treatment with new medicines?: tumour necrosis factor-alpha inhibitors use in four European countries
    Joëlle M Hoebert
    Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, The Netherlands
    Health Policy 104:76-83. 2012
    ..In addition, characteristics both related to national health systems and spending will be assessed to explore possible differences in international utilisation...
  27. ncbi request reprint Economic evaluations of cholesterol-lowering drugs: a critical and systematic review
    Pearl D Gumbs
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceuticals Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Pharmacoeconomics 25:187-99. 2007
    ..In general, piggy-back evaluations tended to score higher on quality and may therefore be more valuable in decision making...
  28. pmc Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase
    Marjolein J Willemen
    Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht, The Netherlands
    Diabetes Care 34:369-74. 2011
    ..This might result in an increased infection risk. This study assessed the association between use of DPP-4 inhibitors and the reporting of infections...
  29. pmc Drug development for exceptionally rare metabolic diseases: challenging but not impossible
    Michelle Putzeist
    Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, P, O, Box 80 082, 3508TB Utrecht, The Netherlands
    Orphanet J Rare Dis 8:179. 2013
    ....
  30. ncbi request reprint Restoring trust in the pharmaceutical sector on the basis of the SSRI case
    Juan Francisco Hernandez
    Department of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Drug Discov Today 19:523-7. 2014
    ..Rules, regulations and settlements are indispensable tools but undue regulation is costly and can backfire on the rather sensitive trust relationships in the pharmaceutical sector. ..
  31. doi request reprint Traceability of biopharmaceuticals in spontaneous reporting systems: a cross-sectional study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases
    Niels S Vermeer
    Utrecht Institute for Pharmaceutical Sciences UIPS, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Universiteitsweg 99, 3584CG, Utrecht, The Netherlands
    Drug Saf 36:617-25. 2013
    ..Detailed exposure information should be readily available in systems for postmarketing safety surveillance of biopharmaceuticals, including spontaneous reporting systems (SRSs), in which reports of ADRs are collected...
  32. doi request reprint Today's challenges in pharmacovigilance: what can we learn from epoetins?
    Hans C Ebbers
    Utrecht Institute for Pharmaceutical Sciences UIPS, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands
    Drug Saf 34:273-87. 2011
    ..These incidents provide important insight for improving pharmacovigilance, but also pose new challenges for regulatory decision making...
  33. ncbi request reprint Cardiovascular and psychiatric risk profile and patterns of use in patients starting anti-obesity drugs
    Marjolein J C Willemen
    Division of Pharmacoepidemiology and Pharmacotherapy, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht, The Netherlands
    Pharmacoepidemiol Drug Saf 18:631-8. 2009
    ..The aim was to assess whether baseline characteristics of patients starting anti-obesity drugs differ from those not being prescribed these drugs, and to study patterns of anti-obesity drug use...
  34. pmc Disease history and medication use as risk factors for the clinical manifestation of type 1 diabetes in children and young adults: an explorative case control study
    Soulmaz Fazeli Farsani
    Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    PLoS ONE 9:e87408. 2014
    ..It is not well known what triggers type 1 diabetes to become a clinically overt disease. This explorative study aimed to identify the association between disease history/medication use and the clinical manifestation of type 1 diabetes...
  35. pmc Essential medicines are more available than other medicines around the globe
    Yaser T Bazargani
    Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    PLoS ONE 9:e87576. 2014
    ..We evaluated and compared the availability of essential medicines, and medicines not included in national EMLs, at global and regional levels...
  36. doi request reprint Use of diuretics and the risk of gouty arthritis: a systematic review
    Berdine A A Hueskes
    Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands
    Semin Arthritis Rheum 41:879-89. 2012
    ..To systematically review the literature investigating the relationship between use of diuretics and the risk of gouty arthritis...
  37. doi request reprint Pharmacovigilance of biopharmaceuticals: challenges remain
    Thijs J Giezen
    Utrecht Institute for Pharmaceutical Sciences UIPS, Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht University, Utrecht, The Netherlands
    Drug Saf 32:811-7. 2009
    ..Key messages in safety management of biopharmaceuticals remain: be prepared for the unexpected, be aware of confounding by disease (severity) and maintain exposure ascertainment/traceability throughout the logistical chain...
  38. pmc Impact of over-the-counter restrictions on antibiotic consumption in Brazil and Mexico
    Yared Santa-Ana-Téllez
    WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht, The Netherlands
    PLoS ONE 8:e75550. 2013
    ..The objective of the present study is therefore to evaluate the impact of OTC restrictions (2010) on antibiotics consumption in Brazil and Mexico...
  39. pmc A 10-year analysis of the effects of media coverage of regulatory warnings on antidepressant use in The Netherlands and UK
    Juan Francisco Hernandez
    Department of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    PLoS ONE 7:e45515. 2012
    ..SSRI use trends were analyzed from 2000-2010 in the Netherlands (NL) and the UK, and whether trend changes might be associated with media coverage of regulatory warnings...
  40. doi request reprint Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?
    Alexandra Cameron
    Essential Medicines and Pharmaceutical Policies, World Health Organization, Geneva, Switzerland
    Value Health 15:664-73. 2012
    ..We estimated the savings that could be obtained from a hypothetical switch in medicine consumption from originator brands to lowest-priced generic equivalents for a selection of medicines in 17 countries...
  41. doi request reprint Quality and completeness of utilisation data on biological agents across European countries: tumour necrosis factor alpha inhibitors as a case study
    Joëlle M Hoebert
    Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    Pharmacoepidemiol Drug Saf 20:265-71. 2011
    ..This study characterises the main categories of critical issues in collecting available national utilisation data on tumour necrosis factor alpha (TNFalpha) inhibitors in different European countries...
  42. pmc Regulatory scientific advice in drug development: does company size make a difference?
    Michelle Putzeist
    Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, P O Box 80 082, Utrecht, 3508 TB, The Netherlands
    Eur J Clin Pharmacol 67:157-64. 2011
    ..This may help to increase understanding about the knowledge, strategic, and regulatory gaps companies face during drug development...